Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Maury Raycroft
JEF
Maury Raycroft
Wall Street Analyst
★☆☆☆☆
#2509
on 13Foresight · ranked by our own returns
34%
Success Rate
+2.4%
Average Return
15 of 44 calls profitable · -12.5% vs benchmark
📈 Across the calls we could measure, roughly 34% of Maury Raycroft's ratings turned a profit when each position was held for 1 year — averaging +2.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

34 Buy 6 Hold 0 Sell
Maury's Stock Coverage 44 ratings · 2026-06-19
Company Date Position Consensus Price Target 1-Yr Return
DNTH
Dianthus Therapeutics
Jun 15, 2026 BUY Strong Buy
+8.9% avg upside
29 analysts
$132.00
62.15% Upside
-4.4%
COAG
Hemab Therapeutics Holdings, Inc.
Jun 08, 2026 BUY Strong Buy
+42.7% avg upside
5 analysts
$39.00
39.11% Upside
·
TNGX
Tango Therapeutics
May 14, 2026 HOLD Strong Buy
+24.2% avg upside
14 analysts
$27.00
4.90% Downside
+29.8%
CRBP
Corbus Pharmaceuticals
May 12, 2026 BUY Strong Buy
+338.6% avg upside
20 analysts
$33.00
305.32% Upside
-3.5%
BCYC
Bicycle Therapeutics
Apr 30, 2026 BUY Strong Buy
+504.5% avg upside
20 analysts
$12.00
200.83% Upside
-7.6%
CMPX
Compass Therapeutics
Apr 27, 2026 BUY Strong Buy
+372.3% avg upside
19 analysts
$9.00
342.35% Upside
+1.1%
ERAS
Erasca
Apr 13, 2026 BUY Strong Buy
+38.6% avg upside
14 analysts
$21.00
52.63% Upside
-14.3%
IDYA
IDEAYA Biosciences
Apr 05, 2026 BUY Strong Buy
+55.3% avg upside
29 analysts
$52.00
67.72% Upside
-3.3%
KOD
Kodiak Sciences
Mar 26, 2026 BUY Buy
+37.6% avg upside
11 analysts
$56.00
57.93% Upside
-10.2%
VALN
Valneva
Mar 23, 2026 BUY Strong Buy
+107.9% avg upside
5 analysts
$15.00
179.28% Upside
-12.5%
ENGN
enGene Holdings
Feb 25, 2026 BUY Buy
+478.3% avg upside
13 analysts
$28.00
1527.87% Upside
-82.7%
RZLT
Rezolute
Dec 08, 2025 BUY Strong Buy
+122.3% avg upside
13 analysts
$20.00
293.40% Upside
-67.2%
AUPH
Aurinia Pharmaceuticals
Nov 07, 2025 BUY Strong Buy
-7.1% avg upside
12 analysts
$21.00
28.51% Upside
+12.7%
OPK
Opko Health
Oct 31, 2025 HOLD Strong Buy
+374.3% avg upside
12 analysts
$1.60
12.20% Upside
-16.9%
ALNY
Alnylam Pharma
Oct 30, 2025 BUY Strong Buy
+23.4% avg upside
51 analysts
$549.00
98.27% Upside
-37.1%
BCRX
BioCryst
Oct 14, 2025 BUY Strong Buy
+103.2% avg upside
24 analysts
$15.00
64.03% Upside
+31.3%
BEAM
Beam Therapeutics
Oct 09, 2025 BUY Strong Buy
+51.4% avg upside
25 analysts
$41.00
22.10% Upside
+5.5%
TVTX
Travere Therapeutics
Sep 10, 2025 BUY Strong Buy
-15.9% avg upside
22 analysts
$35.00
35.72% Downside
+90.5%
CELC
Celcuity
Aug 15, 2025 BUY Strong Buy
+40.6% avg upside
16 analysts
$79.00
9.68% Downside
+70.0%
ORIC
Oric Pharmaceuticals
Aug 13, 2025 BUY Strong Buy
+180.1% avg upside
19 analysts
$23.00
167.29% Upside
-15.9%
CRDF
Cardiff Oncology
Jun 24, 2025 HOLD Strong Buy
+736.8% avg upside
18 analysts
$3.50
188.04% Upside
-48.1%
TSHA
Taysha Gene Therapies
Jun 11, 2025 BUY Strong Buy
+103.3% avg upside
21 analysts
$8.00
26.31% Upside
+109.0%
PRME
Prime Medicine, Inc.
May 19, 2025 BUY Strong Buy
+210.0% avg upside
16 analysts
$9.00
182.55% Upside
+102.2%
SLDB
Solid Biosciences
May 16, 2025 BUY Strong Buy
+92.3% avg upside
23 analysts
$15.00
90.90% Upside
+149.8%
SGMO
Sangamo Therapeutics
May 13, 2025 BUY Buy
+5843.7% avg upside
16 analysts
$1.50
753.17% Upside
-69.6%
MREO
Mereo Biopharma Group Plc
Dec 06, 2024 BUY Strong Buy
+1146.9% avg upside
11 analysts
$7.00
2118.35% Upside
-45.4%
MGX
Metagenomi, Inc.
Nov 13, 2024 BUY Strong Buy
+729.0% avg upside
7 analysts
$21.00
1628.41% Upside
-19.4%
TYRA
Tyra Bioscience
Oct 17, 2024 BUY Strong Buy
+57.9% avg upside
17 analysts
$31.00
9.82% Upside
-44.2%
RARE
Ultragenyx Pharmaceutical
Oct 04, 2024 BUY Strong Buy
+142.0% avg upside
36 analysts
$129.00
363.18% Upside
-42.0%
AFMDQ
Affimed
Apr 04, 2024 BUY Buy
+12648900.0% avg upside
15 analysts
$20.00
19999899.94% Upside
·
CUE
Cue Biopharma
Mar 13, 2024 BUY Strong Buy
-66.0% avg upside
9 analysts
$6.00
77.95% Downside
-54.7%
TPST
Tempest Therapeutics
Feb 08, 2024 BUY Buy
+1662.1% avg upside
18 analysts
$15.00
1114.54% Upside
-78.9%
VERA
Vera Therapeutics
Nov 09, 2023 BUY Strong Buy
+91.0% avg upside
19 analysts
$26.00
26.71% Downside
+317.8%
ARWR
Arrowhead Pharmaceuticals
Nov 29, 2022 BUY Strong Buy
-19.1% avg upside
26 analysts
$75.00
7.78% Downside
-3.4%
CRSP
Crispr Therapeutics AG
Sep 29, 2022 BUY Buy
+39.7% avg upside
41 analysts
$159.00
197.40% Upside
-29.6%
BYSI
Beyondspring
Dec 01, 2021 HOLD Hold
+400.8% avg upside
8 analysts
$5.00
210.55% Upside
-88.4%
NTLA
Intellia Therapeutics
Jun 22, 2021 BUY Buy
+153.7% avg upside
37 analysts
$109.00
600.92% Upside
-42.3%
ATRA
Atara Biotherapeutics
Dec 21, 2020 HOLD Buy
+79.8% avg upside
18 analysts
$25.00
150.31% Upside
-30.8%
ZLAB
Zai Lab
Jul 29, 2020 BUY Strong Buy
+223.0% avg upside
13 analysts
$86.00
365.32% Upside
+81.4%
KPTI
Karyopharm Therapeutics
Jun 23, 2020 BUY Strong Buy
+146.1% avg upside
18 analysts
$35.00
287.26% Upside
-47.5%
DTIL
Precision BioSciences
May 18, 2020 BUY Strong Buy
+250.1% avg upside
12 analysts
$25.00
279.34% Upside
+30.1%
BDTX
Black Diamond Therapeutics
Feb 24, 2020 BUY Strong Buy
+987.8% avg upside
12 analysts
$47.00
2765.85% Upside
-14.2%
XENE
Xenon
Aug 10, 2018 BUY Strong Buy
+19.0% avg upside
28 analysts
$16.00
70.07% Downside
·
ABEO
Abeona Therapeutics
May 22, 2018 BUY Strong Buy
+196.6% avg upside
17 analysts
$28.00
391.23% Upside
-57.6%
🔒 39 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Maury Raycroft — Frequently Asked Questions
How accurate are Maury Raycroft's stock ratings?
Based on the calls 13Foresight could measure, about 34% of Maury's ratings were profitable over a one-year hold, with an average return of +2.4% per rating, or -12.5% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Maury ranked on 13Foresight?
Maury Raycroft is currently ranked #2509 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Maury cover?
Maury most recently has ratings on DNTH, COAG, TNGX, CRBP, BCYC, CMPX, ERAS, IDYA, KOD, VALN, ENGN, RZLT and 32 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.